In this article, published in Genetic Engineering and Biotechnology News, Matthew Majewski discusses three alternative reimbursement models to address the pricing challenges payers and manufacturers face to provide patient access to high-cost curative therapies.
To read the full article, click here.
Identifying and optimizing the Medical Affairs talent pool
Insights from the MAPS New Orleans 2025 roundtable session. The session highlighted the essential talent needs—such as competencies, qualifications, and...